Personal Health Libraries for Formerly Incarcerated Individuals

NCT ID: NCT05441306

Last Updated: 2025-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized pilot study to test the acceptance and use of PerHL among formerly incarcerated individuals

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible participants will be enrolled after providing informed consent .Participants will then complete a baseline assessment. After the interview, eligible participants will be randomly assigned to the intervention or control group. The research assistant (RA) will be blinded to the randomization allocation until after the consent process. For the purposes of this study, permuted block randomization with random block sizes of 2, 4 and 6 will be used.

Intervention: Those randomized to the intervention arm will have access to PerHL. The intervention group will watch a demonstration by the RA and will practice using PerHL for 10-15 minutes, i.e. taking a picture of a document and uploading to PerHL, entering specific information, voice recording an appointment reminder. The RA will be responsible for providing technical support and assist with the need for initial support, e.g. phone-call or text-based support. At baseline, participants will be asked to provide a list of every organization they visited that may have health and health-related social information on them and receive consent to request their information to be sent to the participant and the study team on their behalf.

Control: Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart). The RA will give them an informational pamphlet outlining key features of the patient portal and guide them through the steps for signing up for a MyChart account, assist them to sign up, add the standard patient portal MyChart app to their phone, and provide them with the MyChart technical support hotline.

Study Procedures: During the intervention phase, all participants will meet with the RA at baseline, 1- and 3 months. During the study, each participant will be asked to provide at least 5 verified locators who are likely to have knowledge of their whereabouts throughout follow-up. Each participant will be provided with $50 payment to participants for each completion of surveys at baseline, 1, 3 months. In addition, participants will be given $10 each month to travel to a location with free wireless so their information can be uploaded to the cloud and a list of available locations. In total, each participant will receive $180 for participation.

For the 1- and 3-month follow-up period, the RA will ask participants to bring information collected and uploaded in PerHL and additional information that is important to the participant but was not uploaded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Personal Health Information Incarcerated Individuals

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Access to Personal Health Library (PerHL) + MyChart

Participants randomized to the PerHL arm will have access to PerHL and the standard of care patient portal (Epic®MyChart).

Group Type EXPERIMENTAL

Personal Health Library (PerHL) + MyChart

Intervention Type DEVICE

Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).

Control - MyChart

Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).

Group Type ACTIVE_COMPARATOR

Epic®MyChart

Intervention Type DEVICE

Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Personal Health Library (PerHL) + MyChart

Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).

Intervention Type DEVICE

Epic®MyChart

Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older
* English-speaking
* have at least one chronic condition
* engaged in primary care in the community
* have been released from a correctional facility in the past year.

Exclusion Criteria

* visual impairments
* cognitive impairments
* language barriers
* planned relocation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Library of Medicine (NLM)

NIH

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Karen Wang, MD, MHS

Role: PRINCIPAL_INVESTIGATOR

Yale University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yale School of Medicine

New Haven, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kimberly Vasquez, MPH

Role: CONTACT

2123630809

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marisol Foumakoye, MA

Role: primary

203-627-4050

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01LM013477-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2000028862

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Healthy Lifetime - Phase 2
NCT05920733 RECRUITING NA
UG3 Pilot Clinical Trial
NCT07073898 ACTIVE_NOT_RECRUITING NA
ENCOMPASS: Expansion Study C
NCT04791267 COMPLETED NA
iControl Chronic Kidney Disease
NCT03951363 TERMINATED NA